CML and tyrosine kinase inhibition: the hope becomes reality

Affiliations

Comment

Jane F Apperley. Lancet Haematol. 2015 May.

. 2015 May;2(5):e176-7.

doi: 10.1016/S2352-3026(15)00072-1. Epub 2015 Apr 20.

¹ Centre for Haematology, Imperial College London, Hammersmith Hospital, London W12 0NN, UK. Electronic address: j.apperley@imperial.ac.uk.

No abstract available

Comment on

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Sasaki K, et al. Lancet Haematol. 2015 May;2(5):e186-93. doi: 10.1016/S2352-3026(15)00048-4. Epub 2015 Apr 20. Lancet Haematol. 2015. PMID: 26688093 Free PMC article.